Stopped: The study was discontinued by the Sponsor because it did not achieve the primary objective.
Study of safety and efficacy of UNR844 in subjects with presbyopia.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Characterize Dose-response of UNR844 for Change From Baseline in Binocular Distance-corrected Near Visual Acuity (DCNVA) at Month 3
Timeframe: Baseline, Month 3